139 related articles for article (PubMed ID: 10737739)
1. Molecular modeling of the aldose reductase-inhibitor complex based on the X-ray crystal structure and studies with single-site-directed mutants.
Singh SB; Malamas MS; Hohman TC; Nilakantan R; Carper DA; Kitchen D
J Med Chem; 2000 Mar; 43(6):1062-70. PubMed ID: 10737739
[TBL] [Abstract][Full Text] [Related]
2. Probing the inhibitor-binding site of aldose reductase with site-directed mutagenesis.
Hohman TC; El-Kabbani O; Malamas MS; Lai K; Putilina T; McGowan MH; Wane YQ; Carper DA
Eur J Biochem; 1998 Sep; 256(2):310-6. PubMed ID: 9760169
[TBL] [Abstract][Full Text] [Related]
3. Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat.
Wilson DK; Tarle I; Petrash JM; Quiocho FA
Proc Natl Acad Sci U S A; 1993 Nov; 90(21):9847-51. PubMed ID: 8234324
[TBL] [Abstract][Full Text] [Related]
4. Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners.
Mylari BL; Larson ER; Beyer TA; Zembrowski WJ; Aldinger CE; Dee MF; Siegel TW; Singleton DH
J Med Chem; 1991 Jan; 34(1):108-22. PubMed ID: 1899452
[TBL] [Abstract][Full Text] [Related]
5. Aldose and aldehyde reductases: correlation of molecular modeling and mass spectrometric studies on the binding of inhibitors to the active site.
El-Kabbani O; Rogniaux H; Barth P; Chung RP; Fletcher EV; Van Dorsselaer A; Podjarny A
Proteins; 2000 Nov; 41(3):407-14. PubMed ID: 11025551
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, activity, and molecular modeling of new 2, 4-dioxo-5-(naphthylmethylene)-3-thiazolidineacetic acids and 2-thioxo analogues as potent aldose reductase inhibitors.
Fresneau P; Cussac M; Morand JM; Szymonski B; Tranqui D; Leclerc G
J Med Chem; 1998 Nov; 41(24):4706-15. PubMed ID: 9822541
[TBL] [Abstract][Full Text] [Related]
7. Kinetic and spectroscopic evidence for active site inhibition of human aldose reductase.
Nakano T; Petrash JM
Biochemistry; 1996 Aug; 35(34):11196-202. PubMed ID: 8780524
[TBL] [Abstract][Full Text] [Related]
8. Structural studies of aldo-keto reductase inhibition.
Wilson DK; Nakano T; Petrash JM; Quiocho FA
Adv Exp Med Biol; 1997; 414():435-42. PubMed ID: 9059648
[No Abstract] [Full Text] [Related]
9. Merging the binding sites of aldose and aldehyde reductase for detection of inhibitor selectivity-determining features.
Steuber H; Heine A; Podjarny A; Klebe G
J Mol Biol; 2008 Jun; 379(5):991-1016. PubMed ID: 18495158
[TBL] [Abstract][Full Text] [Related]
10. A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil.
Urzhumtsev A; Tête-Favier F; Mitschler A; Barbanton J; Barth P; Urzhumtseva L; Biellmann JF; Podjarny A; Moras D
Structure; 1997 May; 5(5):601-12. PubMed ID: 9195881
[TBL] [Abstract][Full Text] [Related]
11. Structure of human aldose reductase holoenzyme in complex with statil: an approach to structure-based inhibitor design of the enzyme.
El-Kabbani O; Ramsland P; Darmanin C; Chung RP; Podjarny A
Proteins; 2003 Feb; 50(2):230-8. PubMed ID: 12486717
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of human aldehyde reductase: characterization of the active site pocket.
Barski OA; Gabbay KH; Grimshaw CE; Bohren KM
Biochemistry; 1995 Sep; 34(35):11264-75. PubMed ID: 7669785
[TBL] [Abstract][Full Text] [Related]
13. The structure of human recombinant aldose reductase complexed with the potent inhibitor zenarestat.
Kinoshita T; Miyake H; Fujii T; Takakura S; Goto T
Acta Crystallogr D Biol Crystallogr; 2002 Apr; 58(Pt 4):622-6. PubMed ID: 11914486
[TBL] [Abstract][Full Text] [Related]
14. A potent aldose reductase inhibitor, (2S,4S)-6-fluoro-2', 5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide (Fidarestat): its absolute configuration and interactions with the aldose reductase by X-ray crystallography.
Oka M; Matsumoto Y; Sugiyama S; Tsuruta N; Matsushima M
J Med Chem; 2000 Jun; 43(12):2479-83. PubMed ID: 10882376
[TBL] [Abstract][Full Text] [Related]
15. Kinetics and molecular docking studies of an anti-diabetic complication inhibitor fucosterol from edible brown algae Eisenia bicyclis and Ecklonia stolonifera.
Jung HA; Islam MN; Lee CM; Oh SH; Lee S; Jung JH; Choi JS
Chem Biol Interact; 2013 Oct; 206(1):55-62. PubMed ID: 23994501
[TBL] [Abstract][Full Text] [Related]
16. Selectivity determinants of the aldose and aldehyde reductase inhibitor-binding sites.
El-Kabbani O; Podjarny A
Cell Mol Life Sci; 2007 Aug; 64(15):1970-8. PubMed ID: 17497245
[TBL] [Abstract][Full Text] [Related]
17. X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.
Ruiz FX; Cousido-Siah A; Mitschler A; Farrés J; Parés X; Podjarny A
Chem Biol Interact; 2013 Feb; 202(1-3):178-85. PubMed ID: 23295227
[TBL] [Abstract][Full Text] [Related]
18. Novel insights into the structural requirements for the design of selective and specific aldose reductase inhibitors.
Kumar H; Shah A; Sobhia ME
J Mol Model; 2012 May; 18(5):1791-9. PubMed ID: 21833829
[TBL] [Abstract][Full Text] [Related]
19. Highly selective aldose reductase inhibitors. 3. Structural diversity of 3-(arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic acids.
Kotani T; Nagaki Y; Ishii A; Konishi Y; Yago H; Suehiro S; Okukado N; Okamoto K
J Med Chem; 1997 Feb; 40(5):684-94. PubMed ID: 9057855
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, in vitro and in silico investigation of aldose reductase inhibitory effects of new thiazole-based compounds.
Sever B; Altıntop MD; Demir Y; Akalın Çiftçi G; Beydemir Ş; Özdemir A
Bioorg Chem; 2020 Sep; 102():104110. PubMed ID: 32739480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
